Compare Icl Group Ltd (ICL) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Oscar Health Inc — how do they compare? Icl Group Ltd trades at $5.03 (market cap $6.47B), while Oscar Health Inc trades at $33.25 (market cap $10.22B). The key difference: Oscar Health Inc is the larger of the two by market cap, and Icl Group Ltd pays a 4.11% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Oscar Health Inc for 15 Days on average.
| ICL | OSCR | |
|---|---|---|
Market Cap | $6.47B | $10.22B |
Volume | 1,387,140 | 4,123,394 |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $33.81 |
52-Week Low | $4.80 | $10.85 |
Typical Hold Time | 56 Days | 15 Days |
Enterprise Value | $9.11B | $6.57B |
Dividend Yield | 4.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL Group trades at $5.015, down 1.28% today, with a bearish technical outlook despite recent earnings beats. The company maintains stable cash flow generation with $1.06B from operations in 2025, though revenue has declined from $10.0B in 2022 to $7.15B in 2025. Recent Q2 2026 results showed earnings of $0.12 per share, beating estimates, and the company announced a dividend of $0.06 payable September 16, 2026.
While ICL shows fundamental stability with reasonable valuation metrics (P/E 20.83, P/S 0.84), the stock faces headwinds from declining profitability margins and bearish technical signals. Analyst consensus remains neutral with 100% hold ratings, though the $6.08 price target suggests 21% upside potential from current levels.
OSCR trades at $33.05, up 0.43% today, with strong technical momentum indicated by bullish moving averages. The company shows impressive growth with Q1 and Q2 2026 EPS beats and projected 2026 revenue of $15.3B. Valuation metrics appear reasonable with P/S of 0.63 and EV/EBITDA of 7.79, while profitability metrics show significant improvement from 2025 losses to projected 2026 net income of $551M.
The outlook remains positive with analyst consensus at $34.00 target and Strong Buy ratings from Zacks. Key opportunities include ACA market share gains and margin expansion, while risks center on rising medical costs and execution of growth targets. The stock faces near-term resistance at $34 with RSI suggesting potential overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
